Roles of IFN-γ in tumor progression and regression: a review

Dragica Jorgovanović, Mengjia Song, Liping Wang, Yi Zhang

View at source ↗PDF ↗Review1,233 citations

Abstract

BACKGROUND: Interferon-γ (IFN-γ) plays a key role in activation of cellular immunity and subsequently, stimulation of antitumor immune-response. Based on its cytostatic, pro-apoptotic and antiproliferative functions, IFN-γ is considered potentially useful for adjuvant immunotherapy for different types of cancer. Moreover, it IFN-γ may inhibit angiogenesis in tumor tissue, induce regulatory T-cell apoptosis, and/or stimulate the activity of M1 proinflammatory macrophages to overcome tumor progression. However, the current understanding of the roles of IFN-γ in the tumor microenvironment (TME) may be misleading in terms of its clinical application. MAIN BODY: Some researchers believe it has anti-tumorigenic properties, while others suggest that it contributes to tumor growth and progression. In our recent work, we have shown that concentration of IFN-γ in the TME determines its function. Further, it was reported that tumors treated with low-dose IFN-γ acquired metastatic properties while those infused with high dose led to tumor regression. Pro-tumorigenic role may be described through IFN-γ signaling insensitivity, downregulation of major histocompatibility complexes, upregulation of indoleamine 2,3-dioxygenase, and checkpoint inhibitors such as programmed cell death ligand 1. CONCLUSION: Significant research efforts are required to decipher IFN-γ-dependent pro- and anti-tumorigenic effects. This review discusses the current knowledge concerning the roles of IFN-γ in the TME as a part of the complex immune response to cancer and highlights the importance of identifying IFN-γ responsive patients to improve their sensitivity to immuno-therapies.

Abstract of "Roles of IFN-γ in tumor progression and regression: a review" by Dragica Jorgovanović, Mengjia Song, Liping Wang et al., https://doi.org/10.1186/s40364-020-00228-x, used under its Creative Commons Attribution license (CC-BY); markup removed, otherwise unmodified.

Record

Archive ID
doi:10.1186/s40364-020-00228-x
Published
Sep 29, 2020
Venue
Biomarker Research
DOI
10.1186/s40364-020-00228-x
PubMed
33005420
Categories
Cancer Immunotherapy and Biomarkers
License
cc-by
Provenance
openalex

Topics